Claims for Patent: 9,284,367

Summary for Patent: 9,284,367

Title:	Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
Abstract:	Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s):	Imran; Mir (Los Altos Hills, CA)
Assignee:	RANI THERAPEUTICS, LLC (San Jose, CA)
Application Number:	13/538,823
Patent Claims:	1. A therapeutic preparation comprising natalizumab, the preparation shaped as a solid tissue penetrating member shaped and configured to penetrate and be inserted into an intestinal wall after oral ingestion by an application of mechanical force upon a surface of the solid tissue penetrating member from an expandable member operably coupled to the solid tissue penetrating member, wherein upon insertion, the tissue penetrating member remains in intestinal tissue to release natalizumab into the blood stream from the intestinal wall by degradation of the tissue penetrating member; wherein the tissue penetrating member is fabricated from the preparation itself. 2. The preparation of claim 1, wherein all of the preparation is in solid form. 3. The preparation of claim 1, wherein the preparation is adapted to be orally delivered in a swallowable capsule. 4. The preparation of claim 3, wherein the preparation is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration. 5. The preparation of claim 4, wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state. 6. The preparation of claim 1, wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release natalizumab into the blood stream. 7. The preparation of claim 6, the biodegradable material comprises PGLA, a sugar or maltose. 8. The preparation of claim 1, wherein the preparation comprises at least one pharmaceutical excipient. 9. The preparation of claim 8, wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant. 10. The preparation of claim 9, wherein the binder comprises PEG. 11. The preparation of claim 1, wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release natalizumab into the blood stream. 12. The preparation of claim 11, wherein the biodegradable material comprises maltose or PGLA. 13. The preparation of claim 1, wherein a weight percent of natalizumab in the tissue penetrating member comprises between about 8 to 12%. 14. The preparation of claim 1, wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the intestinal wall after insertion. 15. The preparation of claim 14, wherein the retaining feature comprises at least one of a barb or an inverse taper shape of the tissue penetrating member. 16. The preparation of claim 1, wherein the natalizumab is contained in the tissue penetrating member in a shaped section. 17. The preparation of claim 16, wherein the shaped section has a cylinder or pellet shape. 18. The preparation of claim 1, wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member. 19. The preparation of claim 1, wherein the Cmax achieved by delivering the preparation by insertion into the intestinal wall is substantially greater than a Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall. 20. The preparation of claim 19, wherein the Cmax achieved by delivering the preparation by insertion into the intestinal wall is at least about 100 times greater than the Cmax achieved when the preparation is delivered orally without insertion into the intestinal wall. 21. The preparation of claim 1, wherein the preparation is configured to produce a release of natalizumab of up to about 40 days. 22. The preparation of claim 21, wherein the preparation is configured to release natalizumab to produce a selectable t1/2. 23. The preparation of claim 22, wherein the t1/2 is about 40 days. 24. The preparation of claim 1, wherein a dose of natalizumab in the preparation is in a range from about 1 to 5 mg. 25. The preparation of claim 24, wherein a dose of natalizumab in the preparation is about 3 mg. 26. A solid therapeutic preparation comprising natalizumab, the preparation adapted for insertion into an intestinal wall after oral ingestion by the application of mechanical force upon a surface of the solid preparation from an expandable member operably coupled to the preparation, wherein upon insertion, the preparation remains in intestinal tissue and releases natalizumab into the bloodstream from the intestinal wall y degradation of the preparation to achieve a t1/2 that is greater than a t1/2 for orally ingested natalizumab that is not inserted into the intestinal wall by the application of a mechanical force upon the surface of the solid preparation; wherein a tissue penetrating member is fabricated from the preparation itself. 27. The preparation of claim 26, wherein the t1/2 of the natalizumab inserted into the intestinal wall is at least about 10 times greater than the t1/2 for the orally ingested natalizumab that is not inserted into the intestinal wall.

Details for Patent 9,284,367

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2030-12-23